Pages that link to "Q47445963"

The following pages link to Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma (Q47445963):

Displaying 45 items.

• Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors (Q24678285) (← links)
• CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer (Q28283044) (← links)
• Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor (Q30945124) (← links)
• The Ras-association domain family (RASSF) members and their role in human tumourigenesis (Q31121564) (← links)
• Tumor Suppressor Ras Association Domain Family 5 (RASSF5/NORE1) Mediates Death Receptor Ligand-induced Apoptosis (Q34251431) (← links)
• Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression (Q34695790) (← links)
• DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies (Q35122019) (← links)
• Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma (Q35126668) (← links)
• Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour (Q35163343) (← links)
• The yin and yang of kidney development and Wilms' tumors (Q35173260) (← links)
• DNA Methylation and Flavonoids in Genitourinary Cancers (Q35623184) (← links)
• Expression and roles of Slit/Robo in human ovarian cancer (Q35759877) (← links)
• Epigenetics of kidney cancer and bladder cancer (Q35857807) (← links)
• Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. (Q35911266) (← links)
• Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma (Q36261661) (← links)
• The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma (Q36383883) (← links)
• SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma (Q36694377) (← links)
• Evaluation of the 3p21.3 tumour-suppressor gene cluster (Q36833529) (← links)
• Therapeutic targets in the ARF tumor suppressor pathway. (Q36879301) (← links)
• Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC (Q37089505) (← links)
• CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. (Q37233603) (← links)
• Genome-wide screen of promoter methylation identifies novel markers in melanoma. (Q37287368) (← links)
• An association between overexpression of DNA methyltransferase 3B4 and clear cell renal cell carcinoma (Q37746112) (← links)
• Cadherin 13 in cancer. (Q37770472) (← links)
• Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics (Q37785109) (← links)
• Hypomethylating Agents for Urologic Cancers (Q37854737) (← links)
• The epigenetics of renal cell tumors: from biology to biomarkers. (Q38016153) (← links)
• Evaluating DAPK as a therapeutic target. (Q38168688) (← links)
• The genetic factors contributing to the development of Wilm's tumor and their clinical utility in its diagnosis and prognosis. (Q38764772) (← links)
• Impact of O6-methylguanine-DNA methyltransferase expression on the drug resistance of clear cell renal cell carcinoma (Q38851881) (← links)
• Ras signaling through RASSF proteins (Q38862017) (← links)
• The epigenetic landscape of renal cancer (Q39021700) (← links)
• Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma (Q39739609) (← links)
• Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma (Q40025069) (← links)
• Characterization of a 3;6 translocation associated with renal cell carcinoma. (Q40186267) (← links)
• Quantitative methylation profiling of renal tumors and the discovery of a new generation of molecular markers (Q40340402) (← links)
• Clinical significance of p16INK4A and p14ARF promoter methylation in renal cell carcinoma: a meta-analysis (Q42362790) (← links)
• Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel (Q47789531) (← links)
• SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence (Q48019854) (← links)
• Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer. (Q54309038) (← links)
• Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma (Q56444295) (← links)
• Genetic and epigenetic analyses guided by high resolution whole-genome SNP array reveals a possible role of in Wilms tumour susceptibility (Q57821557) (← links)
• Comparison of PAX-2, RCC antigen, and antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma by fine-needle aspiration (Q81623009) (← links)
• Epigenetics in renal cell cancer: mechanisms and clinical applications (Q88985337) (← links)
• Aberrant RASSF5 gene transcribed region hypermethylation in pediatric hepatoblastomas (Q92715155) (← links)